Interactive Voice Based Administration of the GAD 7
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT04990492 |
Recruitment Status :
Recruiting
First Posted : August 4, 2021
Last Update Posted : April 21, 2022
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment | Phase |
---|---|---|
General Anxiety Disorder | Diagnostic Test: Paper GAD 7 Diagnostic Test: Voice Administered GAD 7 | Not Applicable |
Study Type : | Interventional (Clinical Trial) |
Estimated Enrollment : | 40 participants |
Allocation: | Randomized |
Intervention Model: | Crossover Assignment |
Intervention Model Description: | This study will be a repeated measure, mixed methods design (i.e., it will contain both qualitative and quantitative components). Newly admitted patients will be asked to complete the questionnaires (i.e., GAD 7 and the UEQ) at two different time points (i.e., Baseline and 1-month follow-up). In order to reduce or control for order effects, the procedure will be counterbalanced. |
Masking: | None (Open Label) |
Primary Purpose: | Diagnostic |
Official Title: | Interactive Voice Based Administration of the GAD 7 |
Actual Study Start Date : | June 10, 2021 |
Estimated Primary Completion Date : | May 31, 2022 |
Estimated Study Completion Date : | June 15, 2022 |
Arm | Intervention/treatment |
---|---|
Experimental: Paper Baseline
Half of the participants will complete the GAD 7 in the traditional paper format at their first appointment. At their second appointment 1-month later, they will complete the GAD 7 on the Mirror device equipped with Amazon Alexa.
|
Diagnostic Test: Paper GAD 7
The paper based GAD 7 that is commonly accepted at clinics
Other Name: Clinically Accepted Paper GAD 7 Diagnostic Test: Voice Administered GAD 7 This is the voice based GAD 7 that is administered through a Mirror device equipped with Amazon Alexa software.
Other Names:
|
Experimental: Alexa Baseline
The other half of the participants will complete the GAD 7 on the Mirror device equipped with Amazon in the traditional paper format at their first appointment. At their second appointment 1-month later, they will complete the GAD 7 in the traditional paper format.
|
Diagnostic Test: Paper GAD 7
The paper based GAD 7 that is commonly accepted at clinics
Other Name: Clinically Accepted Paper GAD 7 Diagnostic Test: Voice Administered GAD 7 This is the voice based GAD 7 that is administered through a Mirror device equipped with Amazon Alexa software.
Other Names:
|
- GAD 7 Diagnostic Scores [ Time Frame: Five minutes ]Scores from the self administered assessment for general anxiety disorder
- User Experience Questionnaire [ Time Frame: Five minutes ]Likert based questionnaire on user experience
- Patient's Qualitative Responses [ Time Frame: One minute ]Comments from patient on usability of the device

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 18 Years and older (Adult, Older Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | Yes |
Inclusion Criteria::
- Newly admitted patients to the Oklahoma State University Behavioral Medicine Clinic
Exclusion Criteria:
- Vulnerable populations, such as children (i.e., minors or individuals under the legal age of consent) and individuals who are incarcerated (i.e., prisoners), will be excluded.
- Individuals who are not their own guardian (i.e., those suffering from severe disabilities) will also be excluded.

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04990492
Contact: Jason Beaman, D.O. | 918-561-8269 | jason.beaman@okstate.edu | |
Contact: Luke Lawson, M.A. | 915-241-5853 | luke.lawson@okstate.edu |
United States, Oklahoma | |
OSU Behavioral Health Clinic | Recruiting |
Tulsa, Oklahoma, United States, 75135 | |
Contact: Jason Beaman, D.O. 918-561-8269 jason.beaman@okstate.edu | |
Contact: Luke Lawson, M.A. 918-2364026 luke.lawson@okstate.edu |
Principal Investigator: | Jason Beaman, D.O. | Oklahoma State University Center for Health Sciences |
Documents provided by Oklahoma State University Center for Health Sciences:
Responsible Party: | Oklahoma State University Center for Health Sciences |
ClinicalTrials.gov Identifier: | NCT04990492 |
Other Study ID Numbers: |
2021029 |
First Posted: | August 4, 2021 Key Record Dates |
Last Update Posted: | April 21, 2022 |
Last Verified: | April 2022 |
Individual Participant Data (IPD) Sharing Statement: | |
Plan to Share IPD: | No |
Plan Description: | Aggregate data and findings will be posted on ClinicalTrials.gov. |
Studies a U.S. FDA-regulated Drug Product: | No |
Studies a U.S. FDA-regulated Device Product: | No |
Anxiety Disorders Mental Disorders |